{"id":745144,"date":"2015-07-31T07:10:00","date_gmt":"2015-07-31T07:10:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/"},"modified":"2025-11-07T01:25:02","modified_gmt":"2025-11-07T06:25:02","slug":"in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/","title":{"rendered":"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing"},"content":{"rendered":"<p class=\"bwalignc\">       Global Collaboration Enabled Vaccine to Move from First-in-Human        Studies to Initial Phase 3 Results Within One Year     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (known as MSD outside the US and Canada) said today that its<br \/>\n      investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have<br \/>\n      100 percent efficacy in an analysis of interim data from a Phase 3 ring<br \/>\n      vaccination trial in Guinea. Preliminary conclusions from this study,<br \/>\n      which is continuing, were published on-line today in <i>The Lancet<\/i>.<br \/>\n      The authors report that vaccine efficacy was 100 percent (95% confidence<br \/>\n      interval: 74.7 &#8211; 100%; p=0.0036) following vaccination with a single<br \/>\n      dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated<br \/>\n      individuals were protected against Ebola virus infection within 6 to 10<br \/>\n      days of vaccination.\n    <\/p>\n<p>\n      To date, more than 4,000 participants have received the vaccine in this<br \/>\n      innovative trial, called \u201cEbola \u00e7a suffit\u201d or \u201cEbola, that\u2019s enough.\u201d<br \/>\n      The trial was conducted by a team that included researchers from the<br \/>\n      World Health Organization (WHO), the Norwegian Institute of Public<br \/>\n      Health, the Health Ministry of Guinea and M\u00e9decins sans Fronti\u00e8res,<br \/>\n      among others. The results from this continuing study, as well as other<br \/>\n      studies already underway (see below) and additional studies to be<br \/>\n      conducted, will be used to support worldwide regulatory submissions.\n    <\/p>\n<p>\n      \u201cMerck has an enduring commitment to develop vaccines and medicines that<br \/>\n      address the world\u2019s most devastating infectious diseases,\u201d said Dr.<br \/>\n      Roger M. Perlmutter, president of Merck Research Laboratories. \u201cBuilding<br \/>\n      on pioneering early work by the Public Health Agency of Canada and<br \/>\n      NewLink Genetics Corporation, the extraordinary efforts of the team in<br \/>\n      Guinea and other experts have yielded interim results that suggest a<br \/>\n      potential role for our rVSV-ZEBOV vaccine in the fight against Ebola<br \/>\n      disease.\u201d\n    <\/p>\n<p>\n      <b>About the development of the rVSV-ZEBOV vaccine<\/b>\n    <\/p>\n<p>\n      The rVSV-ZEBOV vaccine was initially engineered with support from the<br \/>\n      Public Health Agency of Canada and was licensed to NewLink Genetics<br \/>\n      Corporation. To make the vaccine, the vesicular stomatitis virus was<br \/>\n      weakened by removing one of its genes, which was then replaced with a<br \/>\n      single Ebola virus gene that cannot cause disease by itself. Vaccinated<br \/>\n      individuals have been shown to develop antibodies against the Ebola<br \/>\n      virus, which could help protect against future infection. The<br \/>\n      significance and durability of this immune response have not been<br \/>\n      determined.\n    <\/p>\n<p>\n      In late 2014, when the current Ebola outbreak was at its most severe,<br \/>\n      Merck licensed rVSV-ZEBOV from NewLink Genetics, with the goal of<br \/>\n      accelerating the assessment of this candidate vaccine. Since that time,<br \/>\n      Merck has helped to enable a broad development program, including the<br \/>\n      interim phase 3 efficacy results released today. To date, the rVSV-ZEBOV<br \/>\n      vaccine has been administered to more than 9,000 people in phase 1, 2<br \/>\n      and 3 clinical trials.\n    <\/p>\n<p>\n      In addition to NewLink and the Public Health Agency of Canada, leading<br \/>\n      global and national health organizations including the National<br \/>\n      Institute of Allergy and Infectious Diseases (NIAID), the Walter Reed<br \/>\n      Army Institute of Research (WRAIR), the Canadian Immunization Research<br \/>\n      Network (CIRN) and the US Army Medical Research Institute of Infectious<br \/>\n      Diseases (USAMRIID) have helped to conduct studies of the rVSV-ZEBOV<br \/>\n      vaccine. Major funders for these studies included the US Department of<br \/>\n      Defense\u2019s (DoD) Defense Threat Reduction Agency (DTRA) and Joint Vaccine<br \/>\n      Acquisition Program (JVAP), the US Department of Health and Human<br \/>\n      Service\u2019s Biomedical Advanced Research Development Authority (BARDA),<br \/>\n      the National Institutes of Health (NIH) and the Wellcome Trust.\n    <\/p>\n<p>\n      In addition to the phase 3 trial in Guinea described above, other<br \/>\n      studies evaluating the rVSV-ZEBOV vaccine include the STRIVE (Sierra<br \/>\n      Leone Trial to Introduce a Vaccine against Ebola) phase 3 study<br \/>\n      currently being conducted by the Sierra Leone College of Medicine and<br \/>\n      Allied Health Sciences (COMAHS), Sierra Leone Ministry of Health and<br \/>\n      Sanitation and the US Centers for Disease Control and Prevention (CDC);<br \/>\n      and the PREVAIL (Partnership for Research on Ebola Vaccines in Liberia)<br \/>\n      phase 2 study being conducted by a Liberia-NIH partnership in Liberia.\n    <\/p>\n<p>\n      Merck is responsible for research, development and manufacturing efforts<br \/>\n      in support of the rVSV-ZEBOV vaccine. Merck has committed to work<br \/>\n      closely with other stakeholders to accelerate the continued development,<br \/>\n      production and, if licensed, distribution of the vaccine.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51153872&amp;newsitemid=20150731005308&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=949f7786e9af1731b32eb7cb64964537\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51153872&amp;newsitemid=20150731005308&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=f455779bd3496ec40ddc00b903f6e579\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51153872&amp;newsitemid=20150731005308&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=11e6471c1b1d2425e4dc28c2ed6abdc7\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51153872&amp;newsitemid=20150731005308&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=f3d6f53f44bee4f87c50253ed4181693\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51153872&amp;newsitemid=20150731005308&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=e9d98ff824ff439b7161246c23c7499c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150731005308r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media Contacts:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Investor        Contacts:<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet . The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 &#8211; 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated individuals were protected against Ebola virus infection within 6 to 10 days of vaccination. To date, more than 4,000 participants have received the vaccine in this innovative trial, called \u201cEbola \u00e7a suffit\u201d or \u201cEbola, that\u2019s enough.\u201d The trial was conducted by a team that included researchers from the World Health Organization (WHO), the Norwegian Institute of Public Health, the Health Ministry of Guinea and M\u00e9decins sans Fronti\u00e8res, among<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,139,64,289,56],"class_list":["post-745144","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-ebola","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet . The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 - 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated individuals were protected against Ebola virus infection within 6 to 10 days of vaccination. To date, more than 4,000 participants have received the vaccine in this innovative trial, called \u201cEbola \u00e7a suffit\u201d or \u201cEbola, that\u2019s enough.\u201d The trial was conducted by a team that included researchers from the World Health Organization (WHO), the Norwegian Institute of Public Health, the Health Ministry of Guinea and M\u00e9decins sans Fronti\u00e8res, among\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\\\/\",\"name\":\"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-07-31T07:10:00+00:00\",\"dateModified\":\"2025-11-07T06:25:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/","og_locale":"en_US","og_type":"article","og_title":"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing - Merck.com","og_description":"Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which is continuing, were published on-line today in The Lancet . The authors report that vaccine efficacy was 100 percent (95% confidence interval: 74.7 - 100%; p=0.0036) following vaccination with a single dose of the rVSV-ZEBOV vaccine. It appeared that all vaccinated individuals were protected against Ebola virus infection within 6 to 10 days of vaccination. To date, more than 4,000 participants have received the vaccine in this innovative trial, called \u201cEbola \u00e7a suffit\u201d or \u201cEbola, that\u2019s enough.\u201d The trial was conducted by a team that included researchers from the World Health Organization (WHO), the Norwegian Institute of Public Health, the Health Ministry of Guinea and M\u00e9decins sans Fronti\u00e8res, among","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:02+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/","name":"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-07-31T07:10:00+00:00","dateModified":"2025-11-07T06:25:02+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/in-interim-results-from-phase-3-study-mercks-investigational-ebola-vaccine-efficacious-study-is-continuing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"In Interim Results from Phase 3 Study, Merck\u2019s Investigational Ebola Vaccine Efficacious; Study is Continuing"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d72eba84-e077-4227-9c12-494573fc8a04","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/In-Interim-Results-from-Phase-3-Study-Mercks-Investigational-Ebola-Vaccine-Efficacious-Study-is-Continuing-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745144\/revisions"}],"predecessor-version":[{"id":3674614,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745144\/revisions\/3674614"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745144"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}